Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
NA
600 participants
INTERVENTIONAL
2021-09-13
2023-01-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
The Effect of Activities-based Subsidy on Body Fat Loss
NCT04954547
A Randomized Incentive-Based Weight Loss Trial in Singapore
NCT01533454
The Weigh Forward, Financial Incentives for Maintenance of Weight Loss
NCT02538783
Financial Incentives for Maintenance of Weight Loss
NCT01900392
Motivations for Weight Loss
NCT00011115
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
1. Control group. Participants will receive only participation fees.
2. One large reward treatment. Participants will be awarded S$X for reaching the PBF goal at the end of 12 weeks.
3. Small wins treatment. Participants in the Small wins treatment condition will also be given 3 triweekly intermediate goals (IGs). Specifically, given the PBF goal, the PBF Loss Target (LT) is the difference between the initial PBF measured at the first visit and the goal, i.e., LT = initial PBF - PBF goal. Then, the IG1 is to achieve 25% of the LT, the IG2 is to achieve 50% of the LT, and the IG3 is to achieve 75% of the LT. The cash rewards that participants will receive are capped by S$X and depend on which IGs participants achieve and whether participants maintain their progress at the end of the 12 weeks.
All participants will be given an individual-tailored 12-week percentage body fat (PBF) goal. The formula for this goal will be set in consultation with medical and fitness professionals (including certified doctors and fitness trainers) to ensure that it is safe, challenging, and achievable. The base formula, which assumes a 5% weight loss as is often defined to be the medically significant level, is:
(P\* W - x\*5%\*W)/(95%\*W)
where P is PBF at baseline (week 1), W is body mass in kg at baseline, P\*W is their body fat mass at baseline, and x, ranging between 0% and 100%, is the parameter that is set in consultation with professionals. At 100%, it implies that all 5% in weight loss is from fat, vice versa.
Because P and W differ between most persons, the formula tailors a different goal to each research subject. The formula is meant to be flexible toward each individual participant's baseline weight and body fat percent. Leveraging the 5% weight loss target, the investigators determined the expected percentage of this weight that is lost as fat, knowing that weight loss includes not only fat loss but also other components such as water loss. In previous studies, for 1 kg loss in weight, on average, 78.8% came from body fat. Hence, the investigators have targeted 80% of weight loss from the participants to come from body fat.
To examine changes in health, objective measurements will be made during scheduled participant visits on Weeks 1, 12, and 24. Measures include height, weight, waist circumference, and PBF. Each participant will also be given a free digital scale for personal use from home. Their weight and PBF data from the scale will be synchronized to a mobile application. The investigators will retrieve with the participant's consent to examine changes throughout the study's duration.
There are a total of 3 scheduled visits. The first in Week 1 allows baseline measures to be determined. During the first visit, the participants will be provided with a Weight Loss Brochure to warn against the harmful effects of excessive weight loss. The second visit in Week 12 marks the end of the treatment and allows treatment effects to be investigated. The last visit in Week 24 checks for post-treatment effects. During all 3 visits, the participants will also complete a Health Risk Assessment Survey. This survey should take no longer than 10 minutes to complete, and the research team will be physically present to assist the participants with it if so required.
Due to the uncertainty of the pandemic, the investigators may hold the second and/or the third research visits virtually (or at least provide an online option) to avoid large gatherings if necessary. For each virtual research visit, the research team will contact the participants through a video call, during which participants will step on the weighing scales and show the readings to the team. If a research visit is held online, the participation fee/rewards will be sent electronically. The research team will still hold physical meetings for those who experience technical difficulties.
To let the participants track their PBF progress, every participant would be given a digital scale for their keeping even after the research has concluded. Referring to the Health Products Act (HPA), this scale would not be defined as a "medical device." The digital scale serves simply, as would a conventional scale, to inform the user on some bodily metric. It does not attempt to make any medical judgment or recommendation for the user. The research team has done testing on the digital scale and is satisfied with the precision of the device. The participants are expected to weigh-in on the scales weekly from home at their convenience. In the middle of each of the 12 weeks (e.g., Wednesday or Thursday), an automated email will be sent to the participants reminding the participants to do so by the end of the week (Sunday). Non-compliance will not be penalized, but participants are strongly encouraged to weigh-in. The following is the complete list of data that the participants will access from the scale's mobile application. The researchers, with the participants' consent, will also retrieve this data for analysis: 1. Basal metabolism rate; 2. BMI; 3. Bone mass; 4. Metabolic age; 5. Muscle mass; 6. PBF; 7. Skeletal muscle weight ratio; 8. Subcutaneous fat; 9. Total body water; 10. Visceral fat; 11. Weight
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
BASIC_SCIENCE
SINGLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Control
Participants in this arm will not receive any intervention.
No interventions assigned to this group
One large reward
Participants in this arm will receive S$300 if they reach the PBF goal at the end of 12 weeks.
One large reward treatment
Participants will be awarded S$300 for reaching the PBF goal at the end of 12 weeks.
Small wins
Participants in this arm will receive cash rewards capped by S$300, depending on which intermediate goals they reach and the PBF at the end of the 12 weeks.
Small wins treatment
The cash rewards that participants will receive are capped by $300 and depend on which IGs they achieve and whether they maintain their progress at the end of the 12 weeks. Specifically, given the PBF goal, the Loss Target (LT) is the difference between the initial PBF measured at the first visit and the PBF goal, i.e., LT = initial PBF - PBF goal. Then, the IG1 is to achieve 25% of the LT, the IG2 is to achieve 50% of the LT, and the IG3 is to achieve 75% of the LT. Participants will earn $75 credits to their accounts on the programme website for reaching each intermediate goal. Also, when they miss IG1 and/or IG3, they can earn the previous missing $75 credits if they reach the IG2 and the LT. At the end of the 12 weeks, they will lose some or all the credits that they have accumulated if they fail to maintain the progress, and they will only receive the corresponding amount in cash
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
One large reward treatment
Participants will be awarded S$300 for reaching the PBF goal at the end of 12 weeks.
Small wins treatment
The cash rewards that participants will receive are capped by $300 and depend on which IGs they achieve and whether they maintain their progress at the end of the 12 weeks. Specifically, given the PBF goal, the Loss Target (LT) is the difference between the initial PBF measured at the first visit and the PBF goal, i.e., LT = initial PBF - PBF goal. Then, the IG1 is to achieve 25% of the LT, the IG2 is to achieve 50% of the LT, and the IG3 is to achieve 75% of the LT. Participants will earn $75 credits to their accounts on the programme website for reaching each intermediate goal. Also, when they miss IG1 and/or IG3, they can earn the previous missing $75 credits if they reach the IG2 and the LT. At the end of the 12 weeks, they will lose some or all the credits that they have accumulated if they fail to maintain the progress, and they will only receive the corresponding amount in cash
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Male
* Between the ages of 25 and 60
* Body mass index (BMI) of between 23 and 27.5
* Own and use a smartphone or tablet
Exclusion Criteria
* Have any reasons why they would not be able to complete a 24-week research program focused on improving health (e.g., plan to move to another country)
* Have a serious medical condition, including one or more of the following conditions: High blood pressure (hypertension), High cholesterol (Hyperlipidaemia), Heart attack (Myocardial infarction), Heart failure, Stroke (Cerebrovascular disease), Chronic obstructive pulmonary disease (COPD), Kidney disease, and Diabetes (Type 2).
25 Years
60 Years
MALE
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Noah Lim
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Noah Lim
Professor
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Noah Lim, PhD
Role: STUDY_DIRECTOR
The Global Asia Institute, The National University of Singapore
Alessandro Del Ponte, PhD
Role: PRINCIPAL_INVESTIGATOR
Institution for Social and Policy Studies, Yale University
Ta-Cheng Huang, PhD
Role: PRINCIPAL_INVESTIGATOR
The Global Asia Institute, The National University of Singapore
Aidas Masiliunas, PhD
Role: PRINCIPAL_INVESTIGATOR
The Global Asia Institute, The National University of Singapore
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
National University of Singapore
Singapore, , Singapore
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Ta-Cheng Huang
Role: primary
References
Explore related publications, articles, or registry entries linked to this study.
Chaston TB, Dixon JB, O'Brien PE. Changes in fat-free mass during significant weight loss: a systematic review. Int J Obes (Lond). 2007 May;31(5):743-50. doi: 10.1038/sj.ijo.0803483. Epub 2006 Oct 31.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
NUS-IRB-2021-48
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.